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ABSTRACT The interactions of three therapeutic agents, viz. the antipsychotics HPD and CPZ, and the antineoplastic
anthracycline DOX, with oxidatively modiﬁed phospholipids were studied by monitoring the quenching of ﬂuorescence of an
incorporated pyrene-labeled lipid derivative. All three drugs bound avidly to the two oxidized PCs bearing either an aldehyde or
carboxylic function at the end of the sn-2 nonanoyl chain, with the highest afﬁnity measured between CPZ and the latter oxidized
lipid. Subsequent dissociation of the above drugs from the oxidized lipids by DNA, acidic phospholipids, and NaCl revealed the
binding of these drugs with the aldehyde lipid to be driven by hydrophobicity similarly to their binding to lysophosphatidylcholine,
whereas a signiﬁcant contribution of electrostatics was evident for the lipid with the carboxylic moiety. These results connect to
previous experimental data, demonstrating the induction by these drugs of oxidative stress and binding to membrane
phospholipids. These issues are elaborated with reference to their clinical use and side effects.
INTRODUCTION
The mechanism(s) of drug action are conventionally ratio-
nalized in terms of their binding as agonists or antagonists to
speciﬁc proteins. However, for compounds acting on the
membrane level other modes of action are also possible,
owing to the principles of biomembrane operations as many
body systems composed of lipids and associated proteins (1).
In brief, there is a wealth of evidence for the control of the
function of both integral and peripheral membrane proteins
by direct interactions with speciﬁc phospholipids. Accord-
ingly, membrane-partitioning compounds may directly in-
terfere with lipid-protein interactions (2). Membranes also
exhibit a rich scale of cooperative phenomena, responsible
for the dynamic microheterogeneity connected to biological
functions (3). Together with physical factors such as tem-
perature, the organization of these complex entities is amena-
ble to perturbation by membrane-associating molecules (4).
Along these lines, we have shown that lipid-binding drugs
alter the lateral organization of membranes and may thus
inﬂuence their functions, without direct interactions with
membrane proteins (5,6).
The number of different lipid species in eukaryotic mem-
branes has been estimated at ;1200 (4). However, even this
ﬁgure is an underestimate, as it excludes lipids generated by
peroxidation, forming upon unsaturated acyl chains reacting
with the so-called ROS (7). The latter, e.g., superoxide radical
anion (O2 ), hydroxyl radical (OH), and hydrogen peroxide
(H2O2), are produced in oxidative processes of cellular
metabolism and accumulate in tissues upon aging as well as
under pathophysiological conditions such as inﬂammation,
leading to a state known as oxidative stress (8). These
compounds are highly reactive toward cellular macromole-
cules, unsaturated lipids in particular, and their overproduc-
tion has been linked with several major diseases such as
cancer, diabetes, schizophrenia, and neurodegenerative dis-
orders, most notably both Parkinson’s and Alzheimer’s
disease (9–12). The changes in the chemical composition of
the lipid bilayer caused by phospholipid peroxidation include
shortening of the acyl chains and a decrease in the degree of
their unsaturation, together with the modiﬁcation of the acyl
chains by polar carbonyl, carboxyl, hydroxide, and peroxide
moieties. The above can be readily expected to result in
alterations in several key physical properties of the bilayer,
including lipid-lipid interactions, the polarity proﬁle, chain
order, lateral pressure proﬁle, as well as thermal phase
behavior, lateral organization, and membrane asymmetry.
These modiﬁcations of the membrane lipid matrix can be
anticipated to modulate the functions and lipid interactions of
the various membrane-associated proteins in addition to
possible ROS-induced direct chemical modiﬁcation of the
proteins themselves (4,13).
We report here on the interactions of three currently used
drugs: the antipsychotics HPD and CPZ, and the antineo-
plastic compound DOX with two biologically pertinent oxi-
datively modiﬁed phospholipids. More speciﬁcally, we studied
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the binding of the above compounds to PazePC and PoxnoPC
(Fig. 1), monitored by a semiquantitative ﬂuorescence quench-
ing assay utilizing a pyrene-labeled phospholipid derivative.
Of the above lipids, PazePC is present in LDL (14), whereas
PoxnoPC has been recognized as the main product of ozone-
mediated oxidation of lung surfactant extract (15). Binding of
these drugs to lysoPC was employed as a control. Notably,
for the above drugs the mechanisms of action responsible for
their clinical and side effect proﬁles have long been subjects
of considerable controversy, yet membrane interactions and
oxidative stress-linked lipid peroxidation have been suggested
to be involved (16,17). Here we show these three drugs to
bind avidly to oxPLs, with both hydrophobicity and elec-
trostatics (for PazePC) accounting for the interaction. To our
knowledge, this constitutes the ﬁrst demonstration of a direct
interaction of clinically used drugs with oxPLs.
MATERIALS AND METHODS
Materials
PazePC, PoxnoPC, POPC, POPS, and lysoPC were obtained from Avanti
Polar Lipids (Alabaster, AL) and PPDPC from K&V Bioware (Espoo,
Finland). HPD, CPZ, DOX, NaCl, Hepes, EDTA, calf thymus DNA, and
polyphosphate were from Sigma (St. Louis, MO) and CaCl2 and DMSO
from Merck (Darmstadt, Germany). The purity of the lipids was checked by
thin layer chromatography on silicic acid-coated plates (Merck), using
chloroform/methanol/water/ammonia (65:20:2:2, v/v) as the eluent. Exam-
ination of the plates after iodine staining or, when appropriate, for ﬂuo-
rescence upon UV illumination revealed no impurities. Concentrations of
the nonﬂuorescent phospholipids were determined gravimetrically with a
high-precision electrobalance (Cahn Instruments, Cerritos, CA), and the
concentration of pyrene containing PPDPC was obtained spectrophotomet-
rically using the molar extinction coefﬁcient e ¼ 42,000 at 344 nm.
Lipid dispersions
Lipid stock solutions were prepared in chloroform and mixed in this solvent
to obtain the desired compositions. Unless otherwise indicated PPDPC
(XPPDPC¼ 0.01) was included as the ﬂuorescent lipid probe. The solvent was
removed under a stream of nitrogen and the lipid residue subsequently
maintained under reduced pressure for at least 2 h. The dry lipid ﬁlms were
then hydrated at 60C for 30 min in 20 mMHepes, 0.1 mMEDTA, pH 7.4 to
yield a ﬁnal concentration of 200 mM. To assure efﬁcient dispersion of the
lipids the solutions were further placed in a bath-type sonicator for 20 min.
During the above procedure the samples were vortexed several times, and
minimal exposure to light was ensured. Subsequently, the dispersions of
oxPLs or lysoPC were divided into proper aliquots and diluted with the
buffer to a ﬁnal lipid concentration of 25 mM for the subsequent use in
ﬂuorescence experiments. This concentration was used as our Langmuir-
balance experiments (see below) revealed PoxnoPC and PazePC to have
CMC of 21.6 and 18.7 mM, respectively, at pH 7.4 (Table 1). For lysoPC a
CMC of 13.8 mM was measured. Large unilamellar POPC/POPS vesicles
were prepared essentially as described above, except omitting sonication and
instead subjecting the hydrated lipid solution to 19 passes through a
polycarbonate ﬁlter (100 nm pore size, Nucleopore, Pleasanton, CA) using a
LiposoFast small volume homogenizer (Avestin, Ottawa, Canada).
Steady-state ﬂuorescence measurements
The binding of HPD, CPZ, and DOX to oxPLs was assessed by monitoring
the efﬁciency of quenching of the ﬂuorescence emission of pyrene
containing phospholipid analog PPDPC by these molecules (2,18,19). The
measurements were conducted with a Perkin-Elmer (Foster City, CA)
LS50B spectroﬂuorometer using 5.0 nm band-passes for both the excitation
and emission beams of 344 and 394 nm, respectively. Two milliliters of 25
mM lipid dispersion were placed into a magnetically stirred four-window
quartz cuvette in a holder thermostated at 25C with a circulating water bath.
Subsequently, 2.5 ml aliquots of 800 mM solution (CPZ and DOX in water
and HPD in DMSO) of one of the drugs were added and the quenching of
pyrene ﬂuorescence was observed. Thereafter, proper aliquots of 5 M NaCl,
2 mM DNA, or 1 mM POPC/POPS (XPOPS ¼ 0.20) LUVs were added to
yield the indicated ﬁnal concentrations. Changes in the pyrene ﬂuorescence
between additions were allowed to stabilize for ;5–20 min, whereafter the
intensity value was recorded and subsequently corrected for sample dilution.
The merits as well as limitations of the use of pyrene-labeled lipids in energy
transfer measurements have been discussed elsewhere (20).
Dynamic light scattering measurements
Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) was used to mea-
sure DLS from lipid dispersions in 10 3 10 mm disposable cuvettes. Data
were analyzed with dedicated software provided by the instrument manu-
facturer. Temperature of the sample compartment was controlled by a Peltier
element and set to 25C.
CMC determination
CMCs, AS, and apparent air-water partitioning coefﬁcients for PazePC,
PoxnoPC, and lysoPC were determined using serial dilutions of the above
lipids in 20 mM Hepes, 0.1 mM EDTA, pH 7.4 up to 48, 45, or 40 mM lipid
(lysoPC, PazePC, and PoxnoPC, respectively) made into 96-well cuvettes.
The surface tensions g of these solutions were measured by the du Nou¨y
maximum pull technique using a computer-controlled 8-channel analyzer
(Delta-8, Kibron, Helsinki, Finland). Data were retrieved and analyzed using
dedicated software (Delta-8 Manager, Kibron). In brief, Gibbs adsorption
isotherm deﬁned by Eq. 1 was used to relate the surface excess G to the
chemical potential m of the molecule under study.
G ¼  1
RT
dg
dm
: (1)
In dilute solutions dm  d ln c, and thus
FIGURE 1 The chemical structures of the two oxidatively modiﬁed
phospholipids used in this study, viz. PazePC and PoxnoPC.
TABLE 1 Surface chemical characteristics of the two
oxidatively modiﬁed phospholipids
CMC, mM Ksw 3 10
3, M1 AS, A˚
2 (apparent)
PazePC 18.7 202 16.0
PoxnoPC 21.6 164 14.0
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G   1
RT
dg
d lnc
; (2)
where c indicates concentration, T temperature, and R¼ 8.314 J K1 mol1.
Molecular interfacial cross sectional area AS can be subsequently obtained
from
AS ¼ 1
NAG
; (3)
where NA is Avogadro’s number. The value for CMC is determined by the
intersection of lines ﬁtted to the slope of the decreasing part of surface
tension versus bulk concentration graph and the following plateau (Fig. 2),
whereas the reciprocal of the K1sw is given by extrapolating the slope to a
surface tension of 72.8 mN/m recorded for the aqueous buffer.
Determination of drug-membrane molar
partition coefﬁcients
The values for Kp were determined from the ﬂuorescence-quenching data by
the method described by Parry et al. (21). In brief, increasing [drug] was
titrated into a dispersion of PazePC, PoxnoPC or lysoPC including the
ﬂuorescent phospholipid analog PPDPC whereafter ﬂuorescence intensity
values corresponding to each drug/oxPL ratio were recorded (series 1).
Subsequently, aliquots of unlabeled oxPL or lysoPC dispersion were added
and again the intensity values were collected (series 2). Using the cubic
interpolation function of Matlab (The MathWorks, Natick, MA) values for
[drug] that would produce identical values of intensity in series 2 to those
measured in series 1 were obtained, assuming each measured intensity value
(i.e., quenching efﬁciency) to correspond to a single mole fraction X of the
drug in the lipid phase, deﬁned by
X ¼ Kp½DT½H2O1Kp½L; (4)
where [DT] and [L] stand for the total drug and lipid concentrations, respec-
tively. Next, the numerical value of Kp was retrieved by minimizing the
difference between the values of X produced by series 1 and 2 by varying Kp.
RESULTS
Quenching due to HPD, CPZ, and DOX of the ﬂuorescence
from the pyrene-labeled phospholipid derivative PPDPC
incorporated in PazePC and PoxnoPC dispersions was
observed, revealing the binding of these drugs to both oxPL
species (Figs. 3 A and 4 A). Upon deprotonation of the
carboxylic function of PazePC this lipid bears a net negative
charge, thus allowing for electrostatic interactions with
cationic drugs. In keeping with the above, all three drugs
were found to bind PazePC with a higher apparent afﬁnity
compared to the zwitterionic PoxnoPC. An increase in ionic
strength led to their partial dissociation from PazePC, as
judged from the RFQ due to added NaCl (Fig. 3 B). However,
the fact that considerable amounts of all three drugs remain
associated with PazePC at [NaCl] far exceeding the physio-
logical 150 mM suggests the involvement of hydrophobicity.
This is substantiated by the data on these drugs and PoxnoPC,
FIGURE 2 Surface tension g versus concentration of (A) PoxnoPC and
(B) PazePC in 20 mM Hepes, 0.1 mM EDTA, pH 7.4. Values in Table
1 were obtained by ﬁtting the Gibbs adsorption isotherm to the measured
data. Experiments were carried out at ambient temperature of ;23C. The
data points represent the mean of three or four measurements with the
respective standard deviations.
FIGURE 3 (A) Binding of DOX (n), CPZ (d), and HPD (:) to PazePC
as revealed by the decrease in the RFI of PPDPC as a function of [drug].
Subsequent detachment of the bound drugs by added (B) NaCl, (C) POPC/
POPS ¼ 8:2 LUVs, or (D) DNA, evident as RFQ compared to the initial
value before addition of the indicated solute. Total lipid concentration in 20
mM Hepes, 0.1 mM EDTA, pH 7.4 was 25 mM. Temperature was
maintained at 25C.
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from which essentially no dissociation of the three com-
pounds was observed even at ;0.8 M NaCl (Fig. 4 B).
Furthermore, lysoPC, which due to the absent sn-2 acyl chain
bears a structural resemblance to the two oxPLs, displayed
behavior essentially identical to that of PoxnoPCwith respect
to both drug binding and lack of their subsequent dissociation
with increasing [NaCl] (Figs. 5, A and B). The formation of
submicellar aggregates of bile salts and ﬂuorescently labeled
lysophosphatidylethanolamines have been shown to be driven
by hydrophobic interactions (22). Considering that these bile
salts (cholate and taurodeoxycholate) share the amphipathic
nature of the drugs used in this study, similar molecular in-
teractions can be expected to account for the binding of the
drugs to lysoPC.
All three drugs have been previously demonstrated to bind
with high afﬁnity to acidic phospholipids (e.g., 6,18,19). It
was therefore of interest to see if they can be dissociated
from the oxPLs by PC/PS mixed vesicles. First, drugs were
titrated into oxPL/PPDPC dispersions. Subsequently, unla-
beled phospholipid vesicles were added and the reversal of
the quenching of PPDPC residing in the oxPL assemblies
was recorded. Addition of POPC/POPS (XPOPS ¼ 0.20)
LUVs into 25 mM PazePC solution led to a slight disso-
ciation of all three drugs from the latter lipid as evidenced by
an increase in ﬂuorescence (Fig. 3 C), most likely reﬂecting a
competition between the carboxylic function of this oxPL
and the anionic PS headgroup as binding sites for these drugs.
Unexpectedly, for PoxnoPC and HPD and CPZ, the addition
of POPC/POPS LUVs caused a further decrease in PPDPC
ﬂuorescence (Fig. 4 C). This could result from Coulombic
attraction between the negatively charged PC/PS LUVs and
PoxnoPC aggregates, the latter bearing a positive net charge
because of the bound cationic drugs. This in turn may induce
lipid mixing between the aggregates and liposomes, includ-
ing transfer of the ﬂuorescent pyrene-labeled lipid analog
from PoxnoPC aggregates to LUVs, and because of higher
afﬁnities of the drugs to PC/PS LUVs, leading to augmented
quenching of PPDPC in these vesicles.
The higher afﬁnities of the drugs to PC/PS vesicles and
hence the more efﬁcient quenching are likely to result from
the lack of electrostatic interaction between the drugs and
PoxnoPC. Changes in particle size upon putative lipid mixing
were assessed by DLS, whereupon a decrease was seen in the
average aggregate diameter from 89.2 nm (corresponding to
100 mM solution of neat POPC/POPS LUVs) to 78.1 nm
upon the addition of PoxnoPC preincubated with HPD (with
ﬁnal concentrations of 25 and 7 mM, respectively). A similar
decrease was evident for CPZ (data not shown). Importantly,
no additional peaks in the size distribution appeared upon
adding PoxnoPC-drug complexes, thus suggesting that the
diminished (apparent) aggregate size results from the com-
plexes interacting with the LUVs. The reason for a decrease
instead of an increase in the aggregate size could be due
FIGURE 4 (A) Binding of DOX (n), CPZ (d), and HPD (:) to PoxnoPC
as revealed by the decrease in the RFI of PPDPC as a function of [drug].
Subsequent detachment of the bound drugs by added (B) NaCl, (C) POPC/
POPS ¼ 8:2 LUVs, or (D) DNA, evident as RFQ compared to the initial
value before addition of the indicated solute. The experimental conditions
were as described in the legend for Fig. 3.
FIGURE 5 (A) Binding of DOX (n), CPZ (d), and HPD (:) to lysoPC as
revealed by the decrease in the RFI of PPDPC as a function of [drug]. (B)
Subsequent detachment of the bound drugs by added NaCl evident as RFQ
compared to the initial value before addition of the salt. The experimental
conditions were as described in the legend for Fig. 3.
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to morphological changes induced in the liposomes upon
fusion with the PoxnoPC-drug aggregates, thus resulting in a
nonspherical shape (see Discussion).
Quantitative analysis of the afﬁnities of the drugs to the
two oxPLs and lysoPC was carried out by determining their
respective molar lipid/water partition coefﬁcients (Table 2).
Interestingly, the coefﬁcient for partitioning of CPZ to PazePC
was too high to be reliably determined with this technique,
and accordingly, only a rough estimate of.13 108 could be
obtained, indicating at least one order of magnitude higher
afﬁnity than measured between this drug and POPS, 2.2 3
107 (21). However, a stringent comparison of these two Kp
values has to be made with caution since they were deter-
mined for two structurally different membrane systems.
Yet, these data together with the estimated three orders of
magnitude higher Kp of CPZ to PazePC compared to lysoPC
do reveal that the afﬁnity of CPZ to this lipid is indeed very
high. For PoxnoPC the Kp for HPD could not be determined
since the addition of unlabeled PoxnoPC aggregates into a
solution of PPDPC-labeled lipid with bound HPD increased
the ﬂuorescence intensity above the level recorded in the
absence of the drug. The reason behind this behavior may lie
in the lyotropic effect induced by an increase in PoxnoPC
concentration together with the presence of HPD, whereupon
the environment of PPDPC pyrenes residing in the aggre-
gates is altered to increase their quantum yield.
For lysoPC the obtained partition coefﬁcients for CPZ and
DOX were 2–3 times lower compared to PoxnoPC, and only
a minor difference in the Kp of HPD between lysoPC and
PazePC was evident. To explore if PPDPC had an inﬂuence
on the formation of aggregates of oxPLs or their ability to
bind these drug molecules, the association of CPZ with
POPC/POPS/PPDPC (XPOPS ¼ 0.20, XPPDPC ¼ 0.01) LUVs
in the presence of neat PazePC was studied. The association
of CPZ to the LUVs diminished progressively with increas-
ing [PazePC] (Fig. 6), thus revealing that the binding of this
drug to PazePC is not due to the presence of PPDPC in the
oxPL aggregates.
Several of the putative mechanisms of action ascribed to
the antitumor effects of DOX involve interactions with DNA
(17). It was therefore of interest to observe, in accordance
with previous studies revealing a high afﬁnity of DOX to
polynucleotides (19,23), that while the binding of DOX to
both oxPLs persisted in physiological saline, this drug was
readily scavenged from oxPLs by DNA, in contrast to HPD
and CPZ (Figs. 3 D and 4 D). Notably, if DNA was replaced
by polyphosphate (average chain length of 62 residues)
essentially no dissociation of DOX from PazePC was ob-
served even when the sample phosphate concentration was
10-fold higher than the highest concentration present in
similar experiments using DNA (calculated from its back-
bone phosphates; data not shown).
DISCUSSION
Recent studies by our laboratory demonstrated that the two
oxPLs (PazePC and PoxnoPC, Fig. 1) used in this investi-
gation profoundly modify the organization and structural
dynamics of a host phospholipid matrix (13). Based on
monolayer compression isotherms and surface potential data,
it was concluded that the polar functional groups at the ends
of the oxidized sn-2 acyl chains of these lipids reside in the
interfacial region. This location is a consequence of the
oxidized lipids adapting the so-called ‘‘extended’’ lipid
conformation (24,25), in which the sn-2 acyl chains reverse
their orientation to loop back from the membrane hydrocar-
bon region, accommodating in the interface and contacting
the aqueous phase. At high lateral packing densities oxPLs
became solubilized from the monolayers, most likely dis-
solving into the subphase as micellar aggregates (13).
Accordingly, it was of interest to investigate if the above
features of oxPLs would facilitate membrane association of
ligands, such as drugs, by virtue of direct interaction with the
oxidatively modiﬁed phospholipids. At this stage we chose
for this purpose three currently widely used compounds,
HPD, CPZ, and DOX. Although the characterization of the
molecular aggregates formed by the two oxPLs above their
TABLE 2 The Kp between the aqueous phase and the lipid
phase composed by PazePC, PoxnoPC, or lysoPC for the
three drugs used in this study
Drug PazePC PoxnoPC lysoPC
CPZ .1 3 108 1.70 3 106 7.45 3 105
DOX 1.18 3 106 1.92 3 106 5.95 3 105
HPD 4.29 3 105 – 3.50 3 105
The values were obtained after the drug-induced quenching of pyrene-
labeled phospholipid analog (see Materials and Methods).
FIGURE 6 The effect of PazePC on the binding of CPZ to LUVs
composed of 79:20:1 POPC/POPS/PPDPC (total lipid concentration 25 mM
in 20 mM Hepes, 0.1 mM EDTA, pH 7.4). Quenching of RFI of PPDPC is
illustrated in the absence (n) and in the presence of 25 (d), 50 (:), and 100
(;) mM PazePC. Temperature was maintained at 25C.
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respective CMCs in aqueous solutions is currently underway
in our laboratory, at present their exact structural character-
istics remain unresolved.
Based on ﬁxed angle DLS measurements comicelles of
lysoPC and oxPLs retain a size comparable to neat lysoPC
micelles, with the bulk of the sample volume consisting of
aggregates with a diameter of;6 nm up to XoxPL of 0.5 (Fig.
7). However, further increase in the content of the two
oxidized PCs causes the diameter measured by DLS to drop
below 1 nm, a value too small to be realistic for a spherical
(micellar) aggregates. Keeping the above in mind, it is
plausible that the oxPLs in aqueous solutions form non-
spherical aggregates and may induce a similar morphology
in other membrane systems if present above a certain critical
mole fraction. Techniques such as small-angle x-ray scat-
tering are needed to elucidate this issue. Further, surface
tension versus concentration data for PazePC and PoxnoPC,
while readily yielding their respective CMCs, could not be
properly ﬁtted with the Gibbs adsorption isotherm, yielding
unrealistically low AS values for these molecules bearing a
phosphocholine headgroup (Fig. 2, Table 1). Importantly,
however, these complications do not undermine the conclu-
sions of this work, since effects arising from aggregate size
and shape (e.g., variation in curvature) should inﬂuence the
drug binding only in a quantitative manner, not affecting the
observed interactions between the drugs and the two oxPLs.
Two of the drugs shown here to interact with oxidatively
modiﬁed PCs are used in the treatment of schizophrenia. The
pathogenesis of this disease has remained elusive, yet changes
in membrane lipids (26) and elevated activity of phospho-
lipase A2 (27) have been implicated. At this stage it would
certainly be premature to assign even a putative role to the
interaction between the oxPLs and the two antipsychotic
drugs in their mechanism(s) of action. Yet, these interactions
could be relevant and could also be involved in their known
side effects. More speciﬁcally, increased oxidative stress has
been associated with the pathogenesis of tardive dyskinesia
and other extrapyramidal side effects of the antipsychotic
treatment of schizophrenia (28,29). Intriguingly, chronic
exposure to HPD and CPZ has been shown to decrease the
expression and activity of key antioxidant enzymes and to
elevate the level of lipid peroxides in rat brain (30), the
changes induced by HPD being more pronounced. In light of
the results here, it could be speculated that this reﬂects the
lower afﬁnity of HPD to oxPLs (at physiological saline).
Accordingly, avid binding of CPZ to phospholipid oxidation
products may hamper the propagation of free radical chain
reactions and the spreading of oxidative damage due to ROS,
thus possibly explaining at least in part the differences in
the antioxidant status and level of lipid peroxides after the
administration of HPD or CPZ.
The cytotoxicity of DOX is likely to involve several mech-
anisms in addition to those involving its intercalation into
DNA. Generation of ROS and subsequent lipid peroxidation
are known to be involved in the triggering of apoptosis (31).
DOX has been demonstrated to induce apoptosis (32). In-
triguingly, DOX bound to polymer beads and only contacting
the outer surface of the plasmamembrane of cultured cells has
also been shown to be cytotoxic (33). Increased levels of
membrane lipid unsaturation due to dietary supplementation
of polyunsaturated fatty acids have been shown to attenuate
the growth of human breast cancer cells ((34) and references
therein) and to increase their susceptibility to the cytotoxic
effects of DOX (35), including DNA intercalation, inhibition
of topoisomerase II, and augmented ROS production (17). To
this end, DOX may act as an electron acceptor in reactions
catalyzed by intracellular or cell surface-bound oxoreductive
enzymes (36), thus resulting in the formation of a semiqui-
none free radical, which can subsequently autooxidize back
to DOX with a concomitant superoxide radical generation.
Similar redox cycling should be possible for lipid-boundDOX,
thus allowing complexation with oxPLs to build up high drug
concentrations after initial membrane oxidative damage and a
local oxidative attack, especially in the heart with abundance
of mitochondria and low antioxidant levels (37).
The anticancer activity ofDOXmay thus be directly related
to its side effects. Development of acute congestive heart
failure with cumulative DOX doses limits its clinical utility
(38). DOX-induced cardiomyopathy has been suggested to be
caused by the high afﬁnity of this drug to cardiolipin, free
radical generation, and increased oxidative stress (36,39). To
this end, it is of interest that CPZ has also been demonstrated
to be cytotoxic to cancer cells (40). It is plausible that in-
creased ROS production and membrane oxidative damage by
DOX act in parallel to its effects inside the nucleus, perhaps
also by providingmeans for crossing the lipid bilayer barriers.
This is in keeping with studies revealing the tendency of
oxPLs to dissolve from phospholipid monolayers at slightly
FIGURE 7 Size distributions by volume of aggregates of lysoPC and
indicated binary mixtures with oxPLs measured by DLS. LysoPC (n),
lysoPC/PazePC ¼ 8:2 (d), lysoPC/PoxnoPC ¼ 8:2 (:), lysoPC/PazePC ¼
1:1 (;), and lysoPC/PoxnoPC¼ 1:1 (¤). The total lipid concentration in 20
mM Hepes, 0.1 mM EDTA, pH 7.4 was 200 mM in all measurements.
Temperature was maintained at 25C.
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elevated lipid packing densities, with subsequent aggregation
(13). Accordingly, complexation with oxPLs could therefore
aid the diffusion of DOX into the nucleus through cellular
membranes.
Although adding to the complexity of the molecular phar-
macology of processes involving themodiﬁcation of lipids by
ROS, these results certainly warrant further investigation of
the interactions of drugswith oxidized lipids. For comparison,
lysoPC also retained the three compounds studied driven by
hydrophobicity. However, except for the intestinal lumen, the
concentrations of this lipid in cells and tissues are generally
very low. In contrast, although quantitative studies are un-
fortunately still lacking, one may readily expect during oxi-
dative stress the accumulation of signiﬁcant amounts of
PoxnoPC and PazePC, as these are the oxidation products
formed from the most abundant membrane lipid constituents,
PCs bearing unsaturated acyl chains (viz. linoleyl, linolenyl)
in the sn-2 position of the glycerol backbone. As the oxPLs
have very different physicochemical properties from those of
their nonoxidized parent molecules, including their partition-
ing into membranes (13), these lipids and their complexes
with drugs can be readily expected to have a signiﬁcant impact
on the distribution of drugs in the various cellular and tissue
compartments, for instance. Along these lines, drugs may
further either enhance or retard the solubilization of oxPLs
from biomembranes. These issues are now being explored in
our laboratory.
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